Dr. Sam Rothstein, PhD is the CEO and cofounder of Duo Oncology. He has 20 years of experience researching and developing nanoparticle products like the ones licensed by Duo Oncology. Since founding and bootstrapping his first company in 2010, a particle CDMO, Dr. Rothstein has continuously worked in life science startups as a CSO or CEO. During this time, he led $5 million of contracts and Small Business Innovation Research projects developing particle drug products. As a CEO, he has also raised over $4M in private investment since 2020. Prior to founding Duo Oncology, Dr. Rothstein began working at the interface of cancer immunotherapy and drug delivery as the CEO of Qrono Inc in 2017. Dr. Rothstein holds chemical engineering degrees from Bucknell University and the University of Pittsburgh.

Dr. Katherine Eichinger, PharmD, PhD is the Director of Operations for Duo Oncology and holds a master’s degree in clinical research and a doctorate in pharmaceutical science. Dr. Eichinger's experience spans from fundamental bench research to clinical studies and includes operations experience from two major hospital systems. Her more than ten years in preclinical research have led to fourteen publications advancing science in drug pharmacology, immunology, and human disease. She serves as the principal investigator for Duo Oncology’s first STTR from the National Cancer Institute. Her BS, MS, and PharmD degrees were conferred by the University of Michigan. Dr. Eichinger received her PhD from the University of Pittsburgh where she also completed a post-doctoral fellowship.

Dr. Victoria Manax, M.D. is an accomplished medical oncologist with over two decades of expertise in the pharmaceutical/biotech industry with a focus on global drug/device development, medical affairs, and patient advocacy. Dr. Manax has made indelible contributions to the field with her expertise in shaping clinical trial landscapes, particularly in adaptive platform designs with biomarker integration. Renowned for these innovative clinical trial designs, Dr. Manax has played a pivotal role in the development, approval, and launch of billion-dollar products, including the standard of care for pancreatic cancer. Dr. Manax has effectively overseen numerous multimillion-dollar global clinical trial programs, earning her recognition as a respected panelist among regulatory agencies worldwide. She holds multiple clinical advisories, chair positions, and patents, exemplifying her commitment to advancing medical science and patient well-being. In addition to her exceptional career, Dr. Manax is a proud Belfast Ambassador recipient and was recently named as a government advisor to Northern Ireland for Health and Life Sciences, embodying her dedication to advancing healthcare on a global scale.

Dr. José Iglesias, M.D. has a 30+ year career in the pharmaceutical industry, both in large pharma and biotech, and has wide experience in designing and leading all Phases (I-IV) of oncology clinical trials, including 3 large Phase III registration studies. Dr. Iglesias has occupied leadership and senior management positions (CMO, SVP, VP) with department-founding duties in clinical development and medical affairs. Whilst serving as Vice President, Clinical Development, at Celgene Corporation, he was responsible for the Phase III development of Abraxane in pancreatic cancer, lung cancer and metastatic breast cancer. José is author or co-author of more than 60 publications in the area of oncology, with over 9,000 citations. He is an active member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the European Society of Medical Oncology (ESMO).

Dr. Karen Williams, PhD has over 30 years of experience in the pharmaceutical and contract clinical research industries. Dr. Williams started her career in a combined clinical & regulatory role in medical devices before moving completely to clinical research initially at Boehringer Mannheim (now part of Roche) and later, as a freelance consultant, she held roles at Novartis Oncology and Pfizer Oncology. Over the course of her career, Dr. Williams also had positions in both large and small CROs. In 2012, Dr Williams established Karma Oncology, a specialized oncology clinical development provider. Dr. Williams holds a BSc (Hons) in biology, and PhD in bioengineering, from the University of Strathclyde in Glasgow; she is a Fellow of the Institute of Clinical Research, a Member of the Institute of Biology, a Chartered Biologist and a Chartered Scientist.

Dr. Mark Tracy, PhD is Founder and President of, Tracy BioConsulting, LLC. Tracy BioConsulting is a specialty biopharmaceutical consulting firm dedicated to helping clients successfully advance their scientific research into and through the clinic. Dr. Tracy is known internationally for developing innovative first-in class complex injectable and nucleic acid therapeutics. Dr. Tracy played a key role in developing Onpattro®, the first RNAi therapeutic approved by the FDA, EMA and other regulatory agencies worldwide. He also played an important role in the development of lipid nanoparticle technology used in mRNA COVID-19 vaccines granted regulatory approval worldwide. Previously, he developed several complex injectable sustained release products that have been commercialized including Vivitrol®, Bydureon®, and Nutropin® Depot, which was the first long acting protein product approved by the FDA. Dr. Tracy has extensive experience in the development of nano and microparticle-based products and other sterile injectable formulations from research through IND filing and commercialization. He has been recognized by peers internationally for accomplishments and leadership in the pharmaceutical product development, bioengineering, and delivery fields. Dr. Tracy is a Past-President and Fellow of the Controlled Release Society (CRS) and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).

Dr. Jingjing Sun, PhD has more than twelve years of experience developing nanoformulations for cancer therapy, including Duo Oncology's lead product. She is an inventor of seven issued/pending patents in this field. She has also published one book chapter and 46 peer-reviewed papers in top journals. Dr. Sun received her PhD in Polymer Chemistry and Physics from the University of Chinese Academy of Sciences. She is currently an Assistant Professor of Pharmaceutical Sciences at University of Nebraska Medical Center where her research focuses on integrating multiple disciplines (chemistry, bioinformatics, cancer biology and immunology) to develop new nanomedicines.